<DOC>
	<DOCNO>NCT00300118</DOCNO>
	<brief_summary>The purpose study determine whether mesalazine budesonide active treatment active Crohn 's disease .</brief_summary>
	<brief_title>Oral Budesonide v . Oral Mesalazine Active Crohn 's Disease ( CD )</brief_title>
	<detailed_description>Crohn 's disease often treat glucocorticoid mesalazine . Both drug indicate active Crohn 's disease . Treatment mesalazine indicate treatment mildly moderately active Crohn 's disease . Budesonide 9 mg/day mesalazine 4.5 g/day good low dos . So far one trial compare efficacy safety budesonide 5-ASA . The result trial budesonide effective inducing remission mesalazine . The primary objective trial confirm result presentation budesonide mesalazine ; i.e . Budenofalk® capsule ( 9 mg/day ) Salofalk® tablet ( Eudragit-L-coated oral mesalazine ; 4.5 g/day ) moderately active Crohn 's disease . Mesalazine use trial comparator .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Inclusion Criteria ( main ) : Symptoms Crohn 's disease since least 3 month ; diagnosis confirm endoscopic histological , endoscopic radiological criterion [ endoscopy old 12 month old , clinical sign ( e.g . pain localization , pain intensity , blood stool ) behaviour ( accord Vienna classification ) unchanged compare former episode ] Localisation CD either terminal ileum , ascend colon ileocolitis Active phase disease ( 200 &lt; CDAI &lt; 400 ) Exclusion Criteria ( main ) : Known Crohn 's lesion upper GItract ( include jejunum ) present symptom CD rectum currently present Short bowel syndrome Septic complication Baseline stool positive germ cause bowel disease Abscess , perforation active fistula Ileostomy colostomy Resection 50 cm ileum Bowel surgery within last 3 month Immediate surgery require Clinical sign stricturing disease Subileus within last 6 month Suspicion ileus , subileus correspond symptomatology Contraindications , special warning precaution mention SmPC Treatment immunosuppressant , cytostatics , 6TG , methotrexate , cyclosporine within last 3 month ; case treatment azathioprine 6MP drug use maintenance remission dosage unchanged within last 3 month baseline visit study Treatment ketoconazole , ciprofloxacin CYP3A inhibitor within last month baseline visit Treatment antiTNFa therapy within 6 month baseline visit Conventional steroid ( iv , po , rectal ) within 2 week study &gt; 6 mg/d budesonide po &gt; 3 g/d mesalazine po within 2 week study Patients know steroidrefractory steroiddependent former CD episode Treatment study disease oral antibiotic ( e.g. , metronidazole ) within last 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>